BriaCell Therapeutics Corp. (NASDAQ:BCTX – Get Free Report) saw a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 727,600 shares, a growth of 62.0% from the September 30th total of 449,200 shares. Currently, 2.3% of the company’s stock are short sold. Based on an average daily trading volume, of 4,780,000 shares, the short-interest ratio is currently 0.2 days.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. acquired a new stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned approximately 0.44% of BriaCell Therapeutics at the end of the most recent reporting period. 15.42% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of BriaCell Therapeutics in a research report on Thursday, October 3rd.
BriaCell Therapeutics Stock Down 2.6 %
Shares of BriaCell Therapeutics stock opened at $0.87 on Friday. BriaCell Therapeutics has a 52 week low of $0.46 and a 52 week high of $5.97. The firm’s 50 day moving average is $0.79 and its two-hundred day moving average is $1.18. The firm has a market capitalization of $15.85 million, a P/E ratio of -0.69 and a beta of 1.34.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Pros And Cons Of Monthly Dividend Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
